Imaging β-amyloid using [18F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis

被引：0
作者：
Kerstin Heurling
Antoine Leuzy
Eduardo R. Zimmer
Mark Lubberink
Agneta Nordberg
机构：
[1] Uppsala University,Section of Nuclear Medicine and PET, Department of Surgical Sciences
[2] Karolinska Institutet,Department NVS, Centre for Alzheimer Research, Division of Translational Alzheimer Neurobiology
[3] Pontifical Catholic University of Rio Grande do Sul (PUCRS),Brain Institute of Rio Grande do Sul (BraIns)
[4] Federal University of Rio Grande do Sul (UFRGS),Department of Biochemistry
[5] Karolinska University Hospital Huddinge,Department of Geriatric Medicine
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2016年 / 43卷
关键词：
β-amyloid; [; F]Flutemetamol; Vizamyl; Positron emission tomography; Mild cognitive impairment; Alzheimer’s disease;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
In Alzheimer’s disease (AD), the deposition of β-amyloid (Aβ) is hypothesized to result in a series of secondary neurodegenerative processes, leading ultimately to synaptic dysfunction and neuronal loss. Since the advent of the first Aβ-specific positron emission tomography (PET) ligand, 11C-Pittsburgh compound B ([11C]PIB), several 18F ligands have been developed that circumvent the limitations of [11C]PIB tied to its short half-life. To date, three such compounds have been approved for clinical use by the US and European regulatory bodies, including [18F]AV-45 ([18F]florbetapir; Amyvid™), [18F]-BAY94-9172 ([18F]florbetaben; Neuraceq™) and [18F]3′-F-PIB ([18F]flutemetamol; Vizamyl™). The present review aims to summarize and discuss the currently available knowledge on [18F]flutemetamol PET. As the 18F analogue of [11C]PIB, [18F]flutemetamol may be of use in the differentiation of AD from related neurodegenerative disorders and may help with subject selection and measurement of target engagement in the context of clinical trials testing anti-amyloid therapeutics. We will also discuss its potential use in non-AD amyloidopathies.
引用
收藏
页码：362 / 373
页数：11
相关论文
共 412 条
  • [1] Villemagne VL(2011)Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease Ann Neurol 69 181-192
  • [2] Pike KE(2012)Clinical and biomarker changes in dominantly inherited Alzheimer’s disease N Engl J Med 367 795-804
  • [3] Chételat G(2004)Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound-B Ann Neurol 55 306-319
  • [4] Ellis KA(2013)Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods J Nucl Med 54 70-77
  • [5] Mulligan RS(2012)Amyloid imaging in Alzheimer’s disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography J Neurol Neurosurg Psychiatry 83 923-926
  • [6] Bourgeat P(2012)Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer’s disease Eur J Nucl Med Mol Imaging 39 983-989
  • [7] Bateman RJ(2013)Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education. Amyloid Imaging Task Force of the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging Alzheimers Dement 9 e106-e109
  • [8] Xiong C(2014)Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers Eur J Nucl Med Mol Imaging 41 1398-1407
  • [9] Benzinger TL(2013)Positron emission tomography radioligands for in vivo imaging of Aβ plaques J Labelled Comp Radiopharm 56 89-95
  • [10] Fagan AM(2011)Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applications Alzheimers Res Ther 3 31-432
12345678910